



Programme

Annual TBVAC2020 Meeting **1-5 February** (including TBVI symposium)

Hotel Eurotel Victoria
Les Diablerets
Switzerland

Monday 1 and Tuesday 2 February 2016 – Separate internal TBVAC2020 WP meetings

Monday 1 February (afternoon)

15:00-18:00 (*For members of TBVAC2020 only*)

- WP1 (Olivier Neyrolles/Steffen Stenger/Else Marie Agger) - (Room tbc)
- WP5 (Tom Ottenhoff) - (Room tbc)

13.00 – 14.30 Lunch

Tuesday 2 February 2016 (whole day)

08.30-16.30 **Separate internal TBVAC2020 WP meetings** (*For members of TBVAC2020 only*)

- WP1 (Olivier Neyrolles/Steffen Stenger/Else Marie Agger) - (Room tbc)
- WP5 (Tom Ottenhoff) - (Room tbc)

12.00 Lunch

Tuesday 2 February 2016 (afternoon)

14.00-18.00 **Separate internal TBVAC2020 WP meetings** (*For members of TBVAC2020 only*)

- WP2 14.00 – 18.00 (Frank Verreck) - (Room tbc)
- WP3.1 15:00 – 17.00 (Ann Rawkins) - (Room tbc)
- WP3.2 16.30 – 18.00 (Mei Mei Ho) - (Room tbc)
- WP4 18.00 – 19.00 (Helen Mchane) - (Room tbc)



Draft programme TBVI Symposium Wednesday 3 February 2016

“TB vaccines and immunity”

Maison des Congrès, Val-Neige, 1865 Les Diablerets, Switzerland

Programme

08.30 – 08.40 **Opening and Welcome** – Nick Drager, Executive Director TBVI

Unconventional Immunity

Chairs: Tom Ottenhoff & Stefan H.E. Kaufmann

08.40 – 09.15 Human MAIT cells – **David Lewinsohn** (Oregon Health & Science University, USA)

09.15 – 09.50 Murine models to study MAIT cell biology and involvement in infectious diseases and for vaccine development – **Olivier Lantz** (Institut Curie, Paris)

09.50 – 10.25 HLA-E restricted responses in TB – **Simone Joosten** (Leiden University Medical Centre, the Netherlands)

10.25 – 10.55 *Coffee break*

10.55 – 11.30 BCG and trained immunity: vaccination studies, experimental models, epigenetics and immunometabolism – **Rob Arts** (Radboud University Medical Centre, the Netherlands)

Viral Vectors & Respiratory Immunity

Chairs: Lew Schragar & Paul-Henri Lambert

11.30 – 12.05 Lentiviral vectors as a vaccine platform – **Pierre Charneau** (Molecular Virology & Vaccinology, Institut Pasteur, Paris, France)

12.05 – 12.40 Viral vectors and pulmonary TB vaccination strategies – **Helen McShane** (University of Oxford, UK)

12.40 – 13.15 MVA technology in the development of highly complexed TB vaccine candidates – **Geneviève Inchauspé** (Transgene, France)

13.15-14.30 *Lunch*

Viral Vectors & Respiratory Immunity, continued

14.30 – 15.05 Respiratory mucosal immunity and novel TB vaccination strategies – **Zhou Xing** (McMaster Immunology Research Centre, Canada)

15.05 – 15.40 Stimulation of mucosal immunity by pulmonary delivery of live vaccines. A safe and effective strategy against TB - **Nacho Aguilo** (University Zaragoza, Spain)

15.40 – 16.10 *Coffee break*

Updates on Vaccine Candidates & Clinical Development Strategies

Chairs: Nick Drager & Jacqueline Shea

16.10 – 16.25 DAR-901 Phase II POI trial – **Ford von Reyn** (Geisel School of Medicine, USA)

16.25 – 16.40 Update on MTBVAC - **Eugenia Puentes** (Biofabri, Spain)

16.40 – 16.55 Update on VPM1002 – **Leander Grode**, Vakzine Projekt Management, Germany)

16.55 – 17.10 Update on GSK's TB vaccine candidate – **Nadia Ouaked** (GSK Biologicals, Belgium)

17.10 – 17.25 Update on SSI's vaccine R&D – **Peter Andersen** (Statens Serum Institute, Denmark)

Thursday 4 February 2016 Annual project meeting (Maison des Congrès)

(Only for members of TBVAC2020 and invited guests)

- 08.30 - 08.40 Opening Annual project meeting** (chair of the SC-Stefan Kaufmann)
- 08.40 - 10.58 WP 5 Correlates of protection**
- 08.40 - 08.42 Introduction WP 5 (Tom Ottenhoff; LUMC)
- 08.42 - 08.50 Development of the MGIT mycobacterial growth inhibition assay. Rachel Tanner; (UOXF)
- 08.50 - 08.58 *Title to be confirmed* Gerhard Walzl; SUN
- 08.58 - 09.06 T cell differentiation of ESAT-6 and Ag85B-specific cells in M.tb-infected adolescents Thomas Scriba; (SATVI)
- 09.06 - 09.14 Transcriptomic analysis of Long Term LTBI non progressors: a clue to long term protective immunity ? Mike Levin; (IC)
- 09.14 - 09.22 MIGA at SSI, strategy and status Morten Ruhwald; (SSI)
- 09.22 - 09.30 Cell specific gene signatures in treatment of TB January Weiner (MPIIB)
- 09.30 - 09.38 Metabolic profiling in TB converting and non-converting Individuals January Weiner; (MPIIB)
for Jayne Sutherland (MRC)
- 09.38 - 09.46 Immune responses to Mycobacteria Simone Joosten; (LUMC)
- 09.46 - 09.54 Correlates of Infection with M. tuberculosis and protection of a novel TB vaccine candidate in South Korea Sang-Nae Cho; (ITRC)
- 09.54 - 10.02 Effect of antiretroviral therapy on the immune response to tuberculosis in HIV-1 co-infected persons Katalin Wilkinson; UCT
- 10.02 - 10.10 Biomarkers: learning from BCG and LTBI/helminth co-infection Hazel Dockrell/
Steven Smith (LSHTM)
- 10.10 - 10.18 Monocytes and TB disease risk Helen Fletcher; (LSHTM)
- 10.18 - 10.26 LAM specific T cells in TB Steffen Stenger; Uulm
- 10.26 - 10.34 Granule release and cytotoxic mediator-induction by HBHA-stimulated CD4+ T lymphocytes Laetitia Aerts; (LoVMI-ULB)
- 10.34 - 10.42 Update of Biomarkers Research at INMI Delia Goletti; (INMI)
- 10.42 - 10.50 MTBVAC : towards immune protection markers François Spertini; Lerisa Govender; (CHUV)
- 10.50 - 10.58 T cell subsets and plasma biomarkers Nadia Caccamo; (AUOP)
- 11.00 - 11.25 Coffee break**
- 11.25 - 11.45 WP 4 Early clinical development**
- 11.25 - 11.35 Introduction WP 4 Helen McShane; (UOXF)
- 11.35 - 11.45 First in human trial TBVAC2020 François Spertini; (CHUV)
- 11.45 - 12.45 WP 3.2 TB vaccine preclinical development** (TBVAC2020, Norad, Aeras/DFID)
- 11.40 - 11.50 Introduction Mei Mei Ho; (NIBSC/MHRA)
- 11.50 - 12.00 The candidate vaccine antigen HBHA Camille Loch; (IPL)
- 12.00 - 12.10 Mycobacterium bovis BCG Δ zmp1 Peter Sander; (UZH)
- 12.10 - 12.20 PPE15 antigen development (Norad grant) Elena Stylianou; (UOXF)
- 12.20 - 12.30 Formulation optimization of preclinical TB vaccines candidates Christophe Barnier-Quer; (UNIL)
- 12.35 - 13.35 Lunch** (restaurant Eurotel)
- 13.40 - 14.05 WP 6 portfolio management** (Luc Hessel, Vice-chair PMC TBVI)
- 13.40 - 13.55 Portfolio management, stage gating and priority setting criteria and P&CDT support Luc Hessel (TBVI)
- 13.55 - 14.05 Global portfolio advise/ assessment and coordination Barry Walker (Aeras)

14.05 - 15.05	WP 3.1 Head-to-Head testing in animal models	
14.05 - 14.15	Introduction WP 3.1 (Ann Rawkins; PHE)	
14.15 - 14.25	SCID mouse safety/ Standard Mouse efficacy model	Gregory Bancroft; (LSHTM)
14.25 - 14.35	Post-exposure mouse model	Pere Joan Cardona; (IGTP)
14.35 - 14.45	Beijing strain challenge model	Sung Jae Shin; (YU)
14.45 - 14.55	Guinea Pig model	Ann Rawkins, Simon Clark; (PHE, incl. GP prime-boost study DFID grant)
14.55 - 15.05	Adjuvant immunogenicity	Christophe Barnier-Quer; (UNIL)
15.05 - 15.35	Coffee tea break	
15.35 - 17.10	WP 2 Preclinical model development	
15.35 - 15.40	Introduction WP2	Frank Verreck; (BPRC)
15.40 - 15.50	Malnutrition-induced reactivation in mouse model	Thomas Lindenstrøm; SSI)
15.50 - 16.00	Post-exposure vaccination in guinea pig model	Simon Clark; PHE
16.00 - 16.10	Post-exposure vaccination in cattle model	Stephen Gordon; (UCD)and Martin Vordermeier; APHA)
16.10 - 16.20	Myeloid skewing and vaccination in mouse models	Helen Fletcher; (LSHTM)
16.20 - 16.30	Co-morbidity and repeated infection in mouse model	Pere-Joan Cardona; (IGTP)
16.30 - 16.40	Clinical Beijing-type isolates in mouse model	Sung Jae Shin; (YU)
16.40 - 16.50	<i>M tb</i> -SIV co-infection in NHP	Sally Sharpe; (PHE)
16.50 - 17.00	Immune response readout in guinea pig model	Max Bastian; (PEI now FLI)
17.00 - 17.10	NHP model refinement	Frank Verreck; (BPRC)

Friday 5 February 2016 Annual project meeting

08.30 - 09.30	WP 1.1 TB vaccine discovery (Steffen Stenger; UULM)	
08.30 - 08.45	Introduction and overview	Steffen Stenger; (UULM)
08.45 - 09.00	Cryptic epitopes of H64	Claus Aagaard; (SSI)
09.00 - 09.15	Unbiased Mtb-genome-wide Ag-discovery	Mariateresa Coppola;(LUMC)
09.15 - 09.30	HLA peptides identification by SWATH-MS	Ruedi Aebersold; (ETH)
09.30 - 10.30	WP 1.2 Novel delivery systems & immunisation strategies	Else Marie Agger; (SSI)
09.30 - 09.45	Introduction and overview	Else Marie Agger; (SSI)
09.45 - 10.00	Viral-vectored delivery of novel TB antigens	Elena Stylianou; (UOXF)
10.00 - 10.15	Synthetic mycolic acids and their esters : synthesis, inflammatory properties and adjuvant potential	Kris Huygen; (WIV-ISP/Bangor/Ugent)
10.15 - 10.30	Prime-boost mucosal delivery of subunit vaccine for rapid lung recall responses	Joshua Woodworth; (SSI)
10.30 - 11.00	Coffee/tea break	
11.00 - 11.30	WP 1.3 Novel live vaccines (Else Marie Agger; SSI)	
11.00 - 11.10	Introduction and overview WP 1.3	Else Marie Agger; (SSI)
11.10 - 11.20	ESX-secretion systems and impact on vaccine efficacy	Roland Brosch; (IP, Paris)
11.20 - 11.30	Autophagy in mycobacterial infections	Isabelle Vergne;
(IPBS/CNRS)		
11.30 - 12.30	WP 7 project coordination and key developments in the TB vaccine R&D field	
11:30 - 11:40	Update on progress EMI-TB project	Rajko Reljic; (SGUL)
11:40 - 11:55	The WHO End TB Strategy: placing Research at the core of elimination	Christian Lienhardt;(WHO)
11:55 - 12:15	Ethical issues regarding the use of animal models	Jan Langermans; (BPRC)
12:15 - 12:30	Project management	External ethical advisor Danielle Roordink; (TBVI)
12.30 - 12.50	General assembly	
12.50 - 12.55	Closure	